Findings

What do systematic reviews say?

350 questions · 366 findings · 36 reviews · Heart

Sort:Best matchNewest Highest certainty Download CSV

No studies found 50 · 13.7%GRADE not reported 15 · 4.1%Very low 79 · 21.6%Low 121 · 33.1%Moderate 72 · 19.7%High 29 · 7.9%

Education, self‐monitoring plus education, and decision aids vs usual care

Decisional conflict · oral anticoagulant therapy in patients with atrial fibrillation

1 finding from 1 review

Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 721 participants
Low

Summary of findings table for the comparison of 'intensified patient care' vs usual care

Adherence to antipsychotic medication: number of missed doses, average endpoint data, short term (up to 6 months) · People receiving lipid‐lowering medications

Summary of findings table for the comparison of 'intensified patient… probably leads to higher medication adherence at ≤ 6 months compared with 'usual care' (moderate certainty).

1 finding from 1 review

Interventions to improve adherence to lipid‐lowering medication 2016 · Cochrane Headline outcomes only
OR 1.93 [1.29, 2.88]
7 studies · 11204 participants
Moderate

Summary of findings table for the comparison of 'intensified patient care' vs usual care

Medication adherence (dichotomous) · People receiving lipid‐lowering medications

Summary of findings table for the comparison of 'intensified patient… leads to higher medication adherence at > 6 months compared with 'usual care' (high certainty).

1 finding from 1 review

Interventions to improve adherence to lipid‐lowering medication 2016 · Cochrane Headline outcomes only
OR 2.87 [1.91, 4.29]
3 studies · 663 participants
High

Summary of findings table for the comparison of 'intensified patient care' vs usual care

LDL‐C reduction (LDL‐C) · People receiving lipid‐lowering medications

1 finding from 1 review

Interventions to improve adherence to lipid‐lowering medication 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 333 participants
Moderate

Summary of findings table for the comparison of 'intensified patient care' vs usual care

Reduction in total serum cholesterol at ≤ 6 months (mg/dL) · People receiving lipid‐lowering medications

1 finding from 1 review

Interventions to improve adherence to lipid‐lowering medication 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 430 participants
Low

Summary of findings table for the comparison of 'intensified patient care' vs usual care

Reduction in total serum cholesterol at > 6 mos (mg/dL) · People receiving lipid‐lowering medications

1 finding from 1 review

Interventions to improve adherence to lipid‐lowering medication 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 127 participants
High

Carvedilol vs placebo

All‐cause mortality · heart failure in patients with Chagas cardiomyopathy

It is very uncertain whether carvedilol changes all‐cause mortality compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
RR 0.69 [0.12, 3.88]
2 studies · 69 participants
Very low

Rosuvastatin vs placebo

Time to heart decompensation · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Rosuvastatin vs placebo

Disease‐free period at 30, 60 and 90 days · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Rosuvastatin vs placebo

Quality of life · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Very low

Rosuvastatin vs placebo

Adverse events · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Rosuvastatin vs placebo

Hospital readmissions (heart failure‐ or adverse event‐related) · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Carvedilol vs placebo

Cardiac mortality · heart failure in patients with Chagas cardiomyopathy

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 69 participants
GRADE not reported

Carvedilol vs placebo

Time to heart decompensation · heart failure in patients with Chagas cardiomyopathy

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 69 participants
GRADE not reported

Carvedilol vs placebo

Disease‐free period at 30, 60 and 90 days · heart failure in patients with Chagas cardiomyopathy

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 69 participants
GRADE not reported

Carvedilol vs placebo

Overall survival · heart failure in patients with Chagas cardiomyopathy

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Very low

Carvedilol vs placebo

Quality of life · heart failure in patients with Chagas cardiomyopathy

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Carvedilol vs placebo

Adverse events · heart failure in patients with Chagas cardiomyopathy

It is very uncertain whether carvedilol changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
RR 0.92 [0.67, 1.27]
1 study · 30 participants
Very low

Rosuvastatin vs placebo

All‐cause mortality · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported

Rosuvastatin vs placebo

Cardiac mortality · chronic heart failure in Chagas cardiomyopathy patients

1 finding from 1 review

Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
GRADE not reported